Saybrook Capital NC Purchases 18,783 Shares of Kenvue Inc. (NYSE:KVUE)

Saybrook Capital NC increased its position in Kenvue Inc. (NYSE:KVUE) by 6.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 323,480 shares of the company’s stock after acquiring an additional 18,783 shares during the quarter. Kenvue comprises about 1.8% of Saybrook Capital NC’s investment portfolio, making the stock its 15th biggest position. Saybrook Capital NC’s holdings in Kenvue were worth $6,906,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Concurrent Investment Advisors LLC grew its position in Kenvue by 131.9% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 53,517 shares of the company’s stock worth $1,238,000 after purchasing an additional 30,438 shares during the last quarter. Graypoint LLC acquired a new stake in Kenvue in the 3rd quarter worth $233,000. Principal Financial Group Inc. grew its position in Kenvue by 3.2% in the 3rd quarter. Principal Financial Group Inc. now owns 2,364,451 shares of the company’s stock worth $54,690,000 after purchasing an additional 73,542 shares during the last quarter. CWA Asset Management Group LLC acquired a new stake in Kenvue in the 3rd quarter worth $307,000. Finally, Galvin Gaustad & Stein LLC acquired a new stake in Kenvue in the 3rd quarter worth $214,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

NYSE:KVUE opened at $23.46 on Friday. The firm has a market cap of $44.83 billion, a PE ratio of 44.25, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company’s 50-day moving average price is $21.64 and its two-hundred day moving average price is $22.33.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Piper Sandler raised their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. UBS Group decreased their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Citigroup decreased their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $23.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.